Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anne Cropp"'
Autor:
Shannon Puhalla, Michelle E. Melisko, Kimberly L. Blackwell, Polly A. Niravath, Karen L. Smith, Antonio C. Wolff, Kathryn P. Componeschi, Kelly Silvestri, Nadine Tung, Rachel C. Jankowitz, Timothy J. Moynihan, Roisin M. Connolly, Paula R. Pohlmann, Juan M. Marte, Heather A. Parsons, Anne Cropp, Robyn Burns, Nuhad K. Ibrahim, Christine M Cotter, Julie R. Nangia, Rachel A. Freedman, Beverly Moy, Rebecca Gelman, Nan Lin, Mothaffar F. Rimawi, Ian E. Krop, Carey K. Anders, Eric P. Winer, Catherine Van Poznak, Ciara C. O’Sullivan
Publikováno v:
Journal of Clinical Oncology
PURPOSE Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::980d614c743ac2880714d633b0033347
https://pubmed.ncbi.nlm.nih.gov/30940923
https://pubmed.ncbi.nlm.nih.gov/30940923
Publikováno v:
Journal of Clinical Oncology. 37:e18172-e18172
e18172 Background: Desperately ill patients who have exhausted treatment options often seek access to therapy through investigational therapies. Participation in a clinical trial may be one option. When a clinical trial is not an option, physicians a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b44348b2c30340e70d9b994f40ec7ad8
https://doi.org/10.1200/jco.2019.37.15_suppl.e18172
https://doi.org/10.1200/jco.2019.37.15_suppl.e18172
Autor:
Rachel A. Freedman, Roisin M. Connolly, Minetta C. Liu, Nadine Tung, Julie R. Nangia, Carey K. Anders, Anne Cropp, Eric P. Winer, Michelle E. Melisko, Ian E. Krop, Catherine Van Poznak, Sarah Farooq, Rebecca Gelman, Polly A. Niravath, Beverly Moy, Shannon Puhalla, Kimberly L. Blackwell, Nan Lin, Christine M Cotter, Antonio C. Wolff
Publikováno v:
Journal of Clinical Oncology. 35:1005-1005
1005 Background: Evidence-based treatments (tx) for metastatic, HER2+ BCBM are limited. We previously found a central nervous system (CNS) objective response rate (ORR) of 8% (95% CI 2-22%) for the irreversible, EGFR/HER2-targeted kinase inhibitor, n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10d35a00363f7507bd0c78dc84c3b8b9
https://doi.org/10.1200/jco.2017.35.15_suppl.1005
https://doi.org/10.1200/jco.2017.35.15_suppl.1005
Autor:
John Vincent, Joel Neutel, Harold Bays, Nitin Kaila, Christie M. Ballantyne, Anne Cropp, David Plowchalk, Kevin Sweeney, Ellen Wang, William Duggan
Publikováno v:
Journal of the American College of Cardiology. 63(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb231e4f5d6ac733cdb130f1ecd941c